Featured Study Opportunities
The Crohn's & Colitis Foundation utilizes Featured Study Opportunities to collaborate with academic and industry researchers to help enroll patients with Crohn’s disease and ulcerative colitis into clinical studies. The list below highlights our partners' current research studies. Please note that these partners have paid to have their trials posted below. Some partners' studies listed may be recipients of partial or full funding from the Crohn's & Colitis Foundation. This support does not imply recommendation or favor of the Foundation, as the Crohn's & Colitis Foundation does not endorse any particular study.
For a comprehensive listing of all research studies currently recruiting, please click here.
(For e.g NY instead of New York)
Current Results: 31 entries
Primary objective is to evaluate the efficacy of JNJ-77242113 versus placebo in inducing clinical response.
The purpose of the DUET study is to evaluate the efficacy and safety of the investigational combination therapy with two investigational study medications in participants with moderately to severely active Ulcerative Colitis.
The purpose of the DUET study is to evaluate the efficacy and safety of the investigational combination therapy of two investigational medications in participants with moderately to severely active Crohn's disease.
The goal of this study is to see how well the study medicine works to treat ulcerative colitis (UC), as well as to see if the study medicine has any side effects. This study will test different doses of the study medicine in participants with moderate to severe UC to find the dose with the best results.
The main purpose of this study is to evaluate the effect of dupilumab on relieving symptoms of ulcerative colitis and reducing inflammation in the colon.
The primary objective of the study is to evaluate the efficacy and dose response of 3 different dose regimens of TEV‑48574 subcutaneous (sc) administered every 2 weeks (Q2W) in adult patients with IBD (moderate to severe UC or CD) as assessed by induction of clinical remission (UC) and endoscopic response (CD) at week 14.
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately to severely active ulcerative colitis in adolescents (≥ 12 years up to < 18 years of age).
To evaluate the efficacy and safety of ozanimod in pediatric participants with moderately to severely active UC.
To evaluate the efficacy of ozanimod in pediatric participants with moderately to severely active Crohn's disease.
To evaluate the effect of efavaleukin alfa on induction of clinical remission.
The Featured Study Opportunities page is made possible in part by:
